Fmr Llc - Apr 12, 2022 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Signature
Kevin M. Meagher, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
BEAM
Transactions as of
Apr 12, 2022
Transactions value $
-$981,205
Form type
4
Date filed
4/14/2022, 05:13 PM
Previous filing
Mar 11, 2022
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Other $0 -979K -25% $0.00 2.94M Apr 12, 2022 F-Prime Capital Partners Healthcare Fund V LP F1
transaction BEAM Common Stock Other $0 +509K +100889.11% $0.00 510K Apr 12, 2022 Impresa Fund III Limited Partnership F1
transaction BEAM Common Stock Other $0 -509K -99.87% $0.00 663 Apr 12, 2022 Impresa Fund III Limited Partnership F1
transaction BEAM Common Stock Other $0 +138K +4169.54% $0.00 141K Apr 12, 2022 F-Prime Capital Partners Healthcare Advisors Fund V LP F1
transaction BEAM Common Stock Other $0 -128K -90.92% $0.00 12.8K Apr 12, 2022 F-Prime Capital Partners Healthcare Advisors Fund V LP F1
transaction BEAM Common Stock Other $0 +15.4K +453.52% $0.00 18.8K Apr 12, 2022 F-Prime Inc. F1
transaction BEAM Common Stock Other $0 +422K +20.41% $0.00 2.49M Apr 12, 2022 Shares held by persons and entities whose shares are subject to reporting by the undersigned. F1
transaction BEAM Common Stock Sale -$33.6K -663 -100% $50.75 0 Apr 13, 2022 Impresa Fund III Limited Partnership
transaction BEAM Common Stock Sale -$345K -6.8K -36.16% $50.70 12K Apr 13, 2022 F-Prime Inc. F2
transaction BEAM Common Stock Sale -$440K -8.8K -73.34% $50.01 3.2K Apr 13, 2022 F-Prime Inc. F3
transaction BEAM Common Stock Sale -$163K -3.2K -100% $50.80 0 Apr 13, 2022 F-Prime Inc.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.
F2 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.50 to $51.00. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $49.75 to $50.50. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the general partner of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.